false--12-31Q320190000878526696000090470000.0010.001120000000120000000338043793409030133804379340903010.0050.01P1Y0.0010.00110000000100000000000P3MP1YP2YP3YP4Y 0000878526 2019-01-01 2019-09-30 0000878526 2019-10-30 0000878526 2018-12-31 0000878526 2019-09-30 0000878526 2018-01-01 2018-09-30 0000878526 2018-07-01 2018-09-30 0000878526 2019-07-01 2019-09-30 0000878526 us-gaap:CommonStockMember 2017-12-31 0000878526 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000878526 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000878526 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000878526 us-gaap:CommonStockMember 2018-06-30 0000878526 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000878526 2018-04-01 2018-06-30 0000878526 2018-01-01 2018-03-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000878526 us-gaap:RetainedEarningsMember 2018-03-31 0000878526 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000878526 us-gaap:RetainedEarningsMember 2018-06-30 0000878526 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000878526 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 0000878526 2018-06-30 0000878526 2018-03-31 0000878526 us-gaap:RetainedEarningsMember 2018-09-30 0000878526 us-gaap:CommonStockMember 2018-09-30 0000878526 us-gaap:CommonStockMember 2018-03-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000878526 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-01-01 0000878526 us-gaap:RetainedEarningsMember 2017-12-31 0000878526 2017-12-31 0000878526 2018-09-30 0000878526 2019-04-01 2019-06-30 0000878526 2019-06-30 0000878526 us-gaap:AccountingStandardsUpdate201802Member 2019-01-01 0000878526 2019-01-01 2019-03-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000878526 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000878526 us-gaap:CommonStockMember 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000878526 us-gaap:CommonStockMember 2019-03-31 0000878526 us-gaap:RetainedEarningsMember 2019-06-30 0000878526 2019-03-31 0000878526 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000878526 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000878526 us-gaap:RetainedEarningsMember 2019-03-31 0000878526 us-gaap:CommonStockMember 2019-09-30 0000878526 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000878526 us-gaap:CommonStockMember 2019-06-30 0000878526 us-gaap:RetainedEarningsMember 2019-09-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:RetainedEarningsMember 2019-01-01 0000878526 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000878526 us-gaap:RetainedEarningsMember 2018-12-31 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000878526 us-gaap:AccountingStandardsUpdate201802Member us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 0000878526 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000878526 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000878526 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000878526 2021-01-01 2019-09-30 0000878526 2020-01-01 2019-09-30 0000878526 2019-09-30 0000878526 2019-01-01 2019-09-30 0000878526 2018-07-01 2019-09-30 0000878526 us-gaap:UnbilledRevenuesMember 2019-01-01 2019-09-30 0000878526 us-gaap:UnbilledRevenuesMember 2019-09-30 0000878526 us-gaap:UnbilledRevenuesMember 2018-12-31 0000878526 2022-01-01 2019-09-30 0000878526 2023-01-01 2019-09-30 0000878526 us-gaap:CustomerRelationshipsMember 2018-12-31 0000878526 us-gaap:CustomerRelationshipsMember 2019-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-09-30 0000878526 us-gaap:ServiceAgreementsMember 2019-09-30 0000878526 us-gaap:TradeNamesMember 2018-12-31 0000878526 us-gaap:PatentsMember 2019-09-30 0000878526 us-gaap:PatentsMember 2018-12-31 0000878526 us-gaap:TradeNamesMember 2019-09-30 0000878526 us-gaap:SoftwareDevelopmentMember 2018-12-31 0000878526 us-gaap:ServiceAgreementsMember 2018-12-31 0000878526 us-gaap:SoftwareDevelopmentMember 2019-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-12-31 0000878526 us-gaap:PatentsMember 2019-01-01 2019-09-30 0000878526 us-gaap:SoftwareDevelopmentMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000878526 us-gaap:ServiceAgreementsMember 2019-01-01 2019-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-01-01 2019-09-30 0000878526 us-gaap:TradeNamesMember 2019-01-01 2019-09-30 0000878526 us-gaap:SoftwareDevelopmentMember 2019-01-01 2019-09-30 0000878526 us-gaap:SoftwareDevelopmentMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000878526 us-gaap:CustomerRelationshipsMember 2019-01-01 2019-09-30 0000878526 us-gaap:SoftwareDevelopmentMember 2018-01-01 2018-09-30 0000878526 us-gaap:PatentsMember 2019-07-01 2019-09-30 0000878526 us-gaap:ServiceAgreementsMember 2018-01-01 2018-09-30 0000878526 us-gaap:SoftwareDevelopmentMember 2019-07-01 2019-09-30 0000878526 us-gaap:CustomerRelationshipsMember 2019-07-01 2019-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2019-07-01 2019-09-30 0000878526 us-gaap:TradeNamesMember 2018-07-01 2018-09-30 0000878526 us-gaap:PatentsMember 2018-07-01 2018-09-30 0000878526 us-gaap:CustomerRelationshipsMember 2018-07-01 2018-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-07-01 2018-09-30 0000878526 us-gaap:DevelopedTechnologyRightsMember 2018-01-01 2018-09-30 0000878526 us-gaap:ServiceAgreementsMember 2018-07-01 2018-09-30 0000878526 us-gaap:SoftwareDevelopmentMember 2018-07-01 2018-09-30 0000878526 us-gaap:ServiceAgreementsMember 2019-07-01 2019-09-30 0000878526 us-gaap:CustomerRelationshipsMember 2018-01-01 2018-09-30 0000878526 us-gaap:TradeNamesMember 2019-07-01 2019-09-30 0000878526 us-gaap:TradeNamesMember 2018-01-01 2018-09-30 0000878526 us-gaap:PatentsMember 2018-01-01 2018-09-30 0000878526 us-gaap:BuildingMember 2019-09-30 0000878526 us-gaap:ComputerEquipmentMember 2019-09-30 0000878526 us-gaap:LandMember 2019-09-30 0000878526 us-gaap:FurnitureAndFixturesMember 2019-09-30 0000878526 us-gaap:LandMember 2018-12-31 0000878526 us-gaap:BuildingMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2018-12-31 0000878526 us-gaap:FurnitureAndFixturesMember 2018-12-31 0000878526 us-gaap:ComputerEquipmentMember 2018-12-31 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-09-30 0000878526 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2018-12-31 0000878526 ntus:DemonstrationAndLoanedEquipmentMember 2019-09-30 0000878526 ntus:CertainProductsMember 2019-09-30 0000878526 us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0000878526 us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-09-30 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000878526 us-gaap:RestructuringChargesMember 2018-07-01 2018-09-30 0000878526 us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-09-30 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0000878526 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0000878526 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000878526 us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2018-09-30 0000878526 us-gaap:RestructuringChargesMember 2019-07-01 2019-09-30 0000878526 us-gaap:RestructuringChargesMember 2018-01-01 2018-09-30 0000878526 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0000878526 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0000878526 us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0000878526 us-gaap:RestructuringChargesMember 2019-01-01 2019-09-30 0000878526 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000878526 srt:MinimumMember 2019-09-30 0000878526 srt:MaximumMember 2019-09-30 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-01-01 2019-09-30 0000878526 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-09-30 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-09-30 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-09-30 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember 2019-09-30 0000878526 srt:MaximumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0000878526 srt:MinimumMember ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:FederalFundsEffectiveSwapRateMember 2019-01-01 2019-09-30 0000878526 ntus:CreditAgreementMember ntus:CitibankNationalAssociationMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-01-01 2019-09-30 0000878526 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000878526 ntus:ForeignCountriesMember 2019-09-30 0000878526 country:US 2018-12-31 0000878526 country:IE 2019-09-30 0000878526 country:DK 2019-09-30 0000878526 country:DK 2018-12-31 0000878526 country:IE 2018-12-31 0000878526 country:CA 2018-12-31 0000878526 country:US 2019-09-30 0000878526 country:CA 2019-09-30 0000878526 ntus:ForeignCountriesMember 2018-12-31 0000878526 ntus:MedicalSuppliesMember ntus:OtometricsMember 2019-01-01 2019-09-30 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2018-01-01 2018-09-30 0000878526 ntus:NewbornCareProductsMember 2019-01-01 2019-09-30 0000878526 ntus:NeurologyProductsMember 2018-01-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsMember 2019-07-01 2019-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NeurologyProductsMember 2018-01-01 2018-09-30 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2018-07-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NeurologyProductsMember 2018-07-01 2018-09-30 0000878526 ntus:NeurologyProductsMember 2019-01-01 2019-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NewbornCareProductsMember 2018-07-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:OtometricsMember 2018-07-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2018-01-01 2018-09-30 0000878526 ntus:NewbornCareProductsMember 2019-07-01 2019-09-30 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2019-07-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2019-07-01 2019-09-30 0000878526 ntus:NewbornCareProductsMember 2018-01-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2018-01-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:OtometricsMember 2018-01-01 2018-09-30 0000878526 ntus:ServicesMember ntus:NeurologyProductsMember 2019-01-01 2019-09-30 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2018-07-01 2018-09-30 0000878526 ntus:OtometricsMember 2019-01-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsMember 2018-01-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2019-01-01 2019-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NewbornCareProductsMember 2019-07-01 2019-09-30 0000878526 ntus:OtometricsMember 2018-07-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NewbornCareProductsMember 2018-01-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2019-01-01 2019-09-30 0000878526 ntus:OtometricsMember 2018-01-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NewbornCareProductsMember 2019-01-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NewbornCareProductsMember 2018-07-01 2018-09-30 0000878526 ntus:OtometricsMember 2019-07-01 2019-09-30 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2019-07-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsMember 2019-01-01 2019-09-30 0000878526 ntus:NeurologyProductsMember 2019-07-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2018-07-01 2018-09-30 0000878526 ntus:NeurologyProductsMember 2018-07-01 2018-09-30 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2019-01-01 2019-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NeurologyProductsMember 2019-07-01 2019-09-30 0000878526 ntus:MedicalSuppliesMember ntus:OtometricsMember 2019-07-01 2019-09-30 0000878526 ntus:NewbornCareProductsMember 2018-07-01 2018-09-30 0000878526 ntus:ServicesMember ntus:NewbornCareProductsMember 2018-01-01 2018-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:OtometricsMember 2018-07-01 2018-09-30 0000878526 ntus:MedicalSuppliesMember ntus:NeurologyProductsMember 2019-01-01 2019-09-30 0000878526 ntus:DevicesAndSystemsMember ntus:NeurologyProductsMember 2019-07-01 2019-09-30 0000878526 ntus:ForeignCountriesMember 2019-07-01 2019-09-30 0000878526 country:US 2019-01-01 2019-09-30 0000878526 ntus:ForeignCountriesMember 2018-01-01 2018-09-30 0000878526 country:US 2018-07-01 2018-09-30 0000878526 ntus:ForeignCountriesMember 2018-07-01 2018-09-30 0000878526 ntus:ForeignCountriesMember 2019-01-01 2019-09-30 0000878526 country:US 2018-01-01 2018-09-30 0000878526 country:US 2019-07-01 2019-09-30 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-01-01 2019-09-30 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-09-30 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2018-12-31 0000878526 us-gaap:FairValueInputsLevel3Member ntus:MedixMedicalDevicesSRLMember 2019-04-01 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-01-01 2019-09-30 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000878526 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-04-02 2019-04-02 0000878526 ntus:MedixMedicalDevicesSRLMember 2019-08-02 xbrli:pure ntus:plan iso4217:USD iso4217:USD xbrli:shares xbrli:shares ntus:segment
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” or an “emerging growth company” in Rule 12b-2 of the Exchange Act.:
The number of issued and outstanding shares of the registrant’s Common Stock, $0.001 par value, as of October 30, 2019 was 34,090,315.
Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2019 and 2018 (unaudited)
Accounts receivable, net of allowance for doubtful accounts of $9,047 in 2019 and $6,960 in 2018
Common stock, $0.001 par value, 120,000,000 shares authorized; shares issued and outstanding 34,090,301 in 2019 and 33,804,379 in 2018
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding in 2019 and 2018
Weighted average shares used in the calculation of net income (loss) per share:
Interest rate swap designated as a cash flow hedge
Reclassification of stranded tax effects upon adoption of ASU 2018-02
Reclassification of deferred foreign currency related adjustments related to the sale of Medix (See Footnote 17 - Sale of Certain Subsidiary Assets)
Reclassification of stranded tax effects for ASU 2018-02
Net issuance of restricted stock awards
Balances, September 30, 2019
Cumulative-effect adjustment for ASU 2016-16
Balances, September 30, 2018
Impairment charge for sale of entity
Principal payments of financing lease liability
Payment of contingent consideration related to a business combination
1 - Basis of Presentation and Significant Accounting Policies
The accompanying interim condensed consolidated financial statements of Natus Medical Incorporated (“we,” “us,” or “our”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Except where noted below within Note 1, the accounting policies followed in the preparation of the interim condensed consolidated financial statements are consistent in all material respects with those presented in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Interim financial reports are prepared in accordance with the rules and regulations of the Securities and Exchange Commission; accordingly, the reports do not include all of the information and notes required by GAAP for annual financial statements. The interim financial information is unaudited, and reflects all normal adjustments that are, in the opinion of management, necessary for the fair presentation of our financial position, results of operations, and cash flows for the interim periods presented. We have made certain reclassifications to the prior period to conform to current period presentation. The consolidated balance sheet as of December 31, 2018 was derived from audited financial statements but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.
Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. The accompanying condensed consolidated financial statements include our accounts and our wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires lease assets and lease liabilities arising from operating leases to be presented in the statement of financial position. Qualitative along with specific quantitative disclosures are required by lessees and lessors to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 including interim periods within those fiscal years. In July 2018, FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases, which affects narrow aspects of the guidance issued in the amendments in Update 2016-02. In July 2018, the FASB also issued ASU 2018-11, Targeted Improvements. The amendments in ASU 2018-11 provide additional clarification and implementation guidance on certain aspects of the previously issued ASU 2016-02 and have the same effective and transition requirements as ASU 2016-02.
The new standard provides a number of optional practical expedients in transition. We have elected the package of practical expedients, which permits an entity to not reassess prior conclusions about lease identification, lease classification and initial direct costs under the new standard. We have not elected the use-of-hindsight practical expedient or the practical expedient pertaining to land easements; the latter of which is not applicable to us. We made an accounting policy election to keep leases with an initial term of 12 months or less off the balance sheet. We will recognize those lease payments in the Consolidated Statements of Operations on a straight-line basis over the lease term.
The new standard became effective for us on January 1, 2019. We adopted the new standard using the modified retrospective transition method with the effective date as the date of initial application. Upon adoption, we recognized additional new lease assets of approximately $19.5 million and additional lease liabilities of approximately $22.3 million as of January 1, 2019. The standard did not materially affect consolidated net earnings. By electing the effective date as the date of initial application, financial performance has not been adjusted and the disclosures required under the new standard have not been provided for periods prior to January 1, 2019. See Significant Accounting Policies and Note 14 for additional discussion and disclosure.
The adoption of the new standard did not impact our liquidity or debt-covenant compliance under its current agreements.
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350). This update modifies the concept of impairment from the condition that exists when the carrying amount of goodwill exceeds its implied fair value to the condition that exists when the carrying amount of a reporting unit exceeds its fair value. An entity no longer will determine goodwill impairment by calculating the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Instead an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. ASU 2017-04 is effective for our annual and any interim goodwill impairment tests performed on or after January 1, 2020. We elected to early adopt. The adoption of ASU 2017-04 did not have an impact on our consolidated financial statements.
In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220). This update permits a company to reclassify its disproportionate income tax effects of the Tax Cuts and Jobs Act of 2017 (the “2017 Act”) on items within accumulated other comprehensive income (“AOCI”) to retained earnings (termed “stranded tax effects”). Only the stranded tax effects resulting from the 2017 Act are eligible for reclassification. The ASU was effective for us as of January 1, 2019. Upon adoption, we reclassified its stranded tax effects resulting from the 2017 Act of $1.3 million, resulting in a decrease to AOCI and an increase to retained earnings as of January 1, 2019.
In June 2016, the FASB issued ASU 2016-13, Credit Losses (Topic 326). This update requires financial assets measured at amortized cost, such as trade receivables and contract assets, to be presented net of expected credit losses, which may be estimated based on relevant information such as historical experience, current conditions, and future expectation for each pool of similar financial assets. The new guidance requires enhanced disclosures related to trade receivables and associated credit losses. In May 2019, the FASB issued ASU 2019-05 which provides targeted transition relief guidance intended to increase comparability of financial statement information. The guidance for both of these is effective beginning January 1, 2020. We are evaluating the impact, if any, that these pronouncements will have on our consolidated financial statements.
In August 2018, the FASB issued ASU 2018-13 Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. This update amends Topic 820 to add, remove, and clarify disclosure requirements related to fair value measurement disclosure. For calendar year-end entities, the update will be effective for annual periods beginning January 1, 2020, and interim periods within those fiscal years. Early adoption of the amendments is permitted, including adoption in any interim period. As the standard relates only to disclosures, we do not expect the adoption to have a material impact on our consolidated financial statements.
We determine if an arrangement is a lease at inception of the lease. Right-of-use (“ROU”) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent an obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit borrowing rate, generally we use an incremental borrowing rate based on the estimated rate of interest for collateralized borrowing over a similar term of the lease payments at the lease commencement date. We use the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. Our lease terms may include options to exclude or terminate the lease when it is reasonably certain that they will exercise that option. Lease expense for lease payments are recognized on a straight-line basis over the lease term.
Operating leases are included in operating lease ROU assets, accrued liabilities, and operating lease liabilities in our consolidated balance sheet. Finance leases are included in property and equipment, accrued liabilities, and other liabilities in the consolidated balance sheet.
We have lease agreements with lease and non-lease components, which are generally accounted for based on the type of asset. For real estate and telecom leases, we account for these components separately. For equipment leases, such as office equipment and vehicles, we account for the lease and non-lease components as a single lease component.
We consider assets and liabilities to be held for sale when all of the following criteria are met:
Management approves and commits to a formal plan to sell the asset or disposal group;
The assets or disposal group is available for immediate sale in its present condition;
An active program to locate a buyer and other actions required to complete the sale have been initiated;
The sale of the asset or disposal group is expected to be completed within one year;
The asset or disposal group is being actively marketed for sale at a price that is reasonable in relation to the current fair value; and
It is unlikely that significant changes will be made to the plan.
Assets held for sale are not depreciated. Upon designation of the asset or disposal group as held for sale, we record the asset or disposal group at the lower of its carrying value or its estimated fair value, less estimated costs of sale. We consider deferrals accumulated in other comprehensive income, including cumulative currency translation adjustments, in the total carrying value of the disposal group in accordance with GAAP. Any loss resulting from this measurement is recognized on our income statement as a restructuring operating expense in the period in which the held for sale criteria are met and gains, if any are not recognized until the date of sale. We assess the fair value of assets held for sale less any costs to sell each reporting period it remains classified as held for sale and reports any reduction in fair value as an adjustment to the carrying value of the assets held for sale.
2 - Revenue
Unbilled accounts receivable (“AR”) for the periods presented primarily represent the difference between revenue recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue for the periods presented primarily relates to extended service contracts, installation, and training, for which the service fees are billed in advance. The associated deferred revenue is generally recognized ratably over the extended service period or when installation and training are complete.
The following table summarizes the changes in the unbilled AR and deferred revenue balances for the nine months ended September 30, 2019 (in thousands):
Unbilled AR, December 31, 2018
Transferred to Trade Receivable
Unbilled AR, September 30, 2019
Deferred Revenue, December 31, 2018
Deferred Revenue, September 30, 2019
At September 30, 2019, the short-term portion of deferred revenue of $19.2 million and the long-term portion of $4.5 million were included in deferred revenue and other long-term liabilities respectively, in the consolidated balance sheet. As of September 30, 2019, we expect to recognize revenue associated with deferred revenue of approximately $7.2 million in 2019, $12.6 million in 2020, $1.9 million in 2021, $1.0 million in 2022,
and $1.0 million thereafter.
As of September 30, 2019 and December 31, 2018, we have classified $22.8 million and $18.1 million, respectively, of inventories as other assets. This inventory consists primarily of service components used to repair products held by customers pursuant to warranty obligations and extended service contracts, including service components for products we no longer sell, inventory purchased for lifetime buys, and inventory that is turning over at a slow rate. We believe these inventories will be utilized for their intended purpose.
Finite-lived intangible assets are amortized over their weighted average lives, which are 14 years for technology, 10 years for customer related intangibles, 7 years for trade names, 6 years for internally developed software, 13 years for patents, 2 years for service agreements and 11 years weighted average in total.
Internally developed software consists of $14.3 million relating to costs incurred for development of internal use computer software and $2.2 million for development of software to be sold.
The amortization expense amounts shown above include internally developed software not held for sale of $0.2 million and $1.2 million for the three and nine months ended September 30, 2019, respectively which is recorded within our income statement as a general and administrative operating expense.
Expected amortization expense related to definite-lived amortizable intangible assets is as follows (in thousands):
Depreciation expense of property and equipment was approximately $1.6 million and $4.9 million for the three and nine months ended September 30, 2019 and approximately $2.0 million and $4.4 million for the three and nine months ended September 30, 2018.
We provide a warranty for products that is generally one year in length, but in some cases regulations may require us to provide repair or remediation beyond the typical warranty period. If any of the products contain defects, we may incur additional repair and remediation costs. Service for domestic customers is provided by our service centers that perform all service, repair, and calibration services. Service for international customers is provided by a combination of our facilities, vendors on a contract basis, and distributors.
A warranty reserve is included in accrued liabilities for the expected future costs of servicing products. Additions to the reserve are based on management’s best estimate of probable liability. We consider a combination of factors including material and labor costs, regulatory requirements, and other judgments in determining the amount of the reserve. The reserve is reduced as servicing is performed to honor existing warranty and regulatory obligations.
As of September 30, 2019, we have accrued $7.4 million for product related warranties, which includes $2.4 million of estimated costs to bring certain products into regulatory compliance. Our estimate of these costs is primarily based upon the number of units outstanding that may require repair and costs associated with shipping.
Changes in estimate related to product remediation activities
Our estimate of future product warranty costs may vary from actual product warranty costs, and any variance from estimates could impact our cost of sales, operating profits and results of operations.
As of September 30, 2019, we have two active share-based compensation plans, the 2018 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan.
In January 2019, we granted market stock unit (“MSU”) awards to certain employees. These MSUs fully vest on December 31, 2021 and have separate market performance goals than the performance stock unit (“PSU”) awards we grant. Each MSU represents the right to one share of common stock. The actual number of MSUs which will be eligible to vest will be based on the performance of our stock price over the vesting period. The maximum number of MSUs which will be eligible to vest are 200% of the MSUs initially granted. A Monte Carlo simulation model was used to estimate the fair value of the MSUs as of their grant date. This model simulates our stock price movements using certain assumptions, including our stock price.
The terms of all other awards granted during the nine months ended September 30, 2019 and the methods for determining grant-date fair value of the awards are consistent with those described in the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2018.
As of September 30, 2019, unrecognized compensation expense related to the unvested portion of stock options and other stock awards was approximately $12.3 million, which is expected to be recognized over a weighted average period of 2.1 years.